Ap­peals court sides with FDA in law­suit over fat-de­rived stem cell pro­ce­dure

The FDA’s crack down on stem cell clin­ics hawk­ing un­ap­proved prod­ucts for con­di­tions with lim­it­ed op­tions is off and run­ning, with a new court win for the agency at the 11th Cir­cuit of Ap­peals on Wednes­day.

The court found that Flori­da-based US Stem Cell’s bi­o­log­i­cal ma­te­r­i­al im­plant­ed in­to the pa­tient “is not the same as that re­moved,” and the pro­ce­dure “in­tends the stem cells to per­form func­tions af­ter the pro­ce­dure be­yond the ba­sic func­tions the stem cells per­formed pri­or to the pro­ce­dure.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.